VYNE Therapeutics (NASDAQ:VYNE) Shares Up 4.1% – Still a Buy?

Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) rose 4.1% on Thursday . The company traded as high as $1.85 and last traded at $1.78. Approximately 220,884 shares changed hands during trading, an increase of 161% from the average daily volume of 84,516 shares. The stock had previously closed at $1.71.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a research report on Thursday, March 6th.

VYNE Therapeutics Stock Down 4.5 %

The company’s 50 day moving average price is $2.30 and its 200 day moving average price is $2.50. The firm has a market capitalization of $25.86 million, a price-to-earnings ratio of -1.98 and a beta of 1.13.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.14 million. As a group, analysts expect that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Patrick G. Lepore purchased 15,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.92 per share, with a total value of $43,800.00. Following the transaction, the director now owns 51,472 shares of the company’s stock, valued at approximately $150,298.24. This trade represents a 41.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of VYNE Therapeutics

A number of hedge funds have recently modified their holdings of VYNE. Jane Street Group LLC acquired a new position in VYNE Therapeutics in the fourth quarter valued at approximately $68,000. XTX Topco Ltd acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at $70,000. Bridgeway Capital Management LLC purchased a new stake in VYNE Therapeutics during the fourth quarter worth $124,000. Adage Capital Partners GP L.L.C. acquired a new stake in VYNE Therapeutics during the fourth quarter valued at $516,000. Finally, Schonfeld Strategic Advisors LLC increased its holdings in VYNE Therapeutics by 4.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares in the last quarter. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.